Because acquisition of Sarkosyl insolubility is a significant characteristic of deposited Tau in tauopathies [36], [37], we first examined the Sarkosyl insolubility of MAP2 in the brains of AD patients and normal controls (Table S1). This evidence concerns the gene MAPT and Alzheimer disease.